Analyst Josh Jennings from TD Cowen maintained a Buy rating on Stryker and keeping the price target at $435.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Josh Jennings has given his Buy rating due to a combination of factors that highlight Stryker’s strong financial outlook and strategic initiatives. The company has set ambitious long-term financial goals for 2026-28, which include organic sales growth, EPS growth, and free cash flow conversion, mirroring its successful commitments from 2023. Stryker’s ability to meet these targets in the past demonstrates its operational strength and reliability.
Furthermore, Stryker plans to enhance its operating margin by 150 basis points through 2028, an upgrade from its previous goal of 30 basis points annual improvement after 2025. This improvement is expected to be driven by continued market share gains, international expansion, strategic mergers and acquisitions, and a focus on innovation across its business lines. These factors collectively suggest a robust growth trajectory, justifying the Buy rating.
According to TipRanks, Jennings is a 2-star analyst with an average return of 0.6% and a 46.39% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Medtronic, TransMedics Group, and Boston Scientific.
In another report released on November 10, Bank of America Securities also reiterated a Buy rating on the stock with a $450.00 price target.